leadf
logo-loader
viewANGLE PLC

ANGLE PLC's Andrew Newland on 'very exciting' liquid biopsy breakthrough

Andrew Newland, chief executive of ANGLE PLC (LON:AGL,OTCQX:ANPCY) tells Proactive their Parsortix system, which is used to harvest circulating tumour cells from the blood stream associated with cancer, has helped researchers from the Queen Mary University of London's Barts Cancer Institute find two rare cells.

The study of 40 people found that combining them enabled the identification of patients who are 10-times more likely to die of prostate cancer in the short-term.

Quick facts: ANGLE PLC

Price: 53 GBX

AIM:AGL
Market: AIM
Market Cap: £91.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system. Not only have they discovered a method of...

on 19/4/18

2 min read